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S U M M A R Y
Background: While studies have demonstrated higher medium-term mortality for community-acquired
pneumonia (CAP), mortality and costs have not been characterized for healthcare-associated pneumonia
(HCAP) over a 1-year period.
Methods: We conducted a retrospective cohort study to evaluatemortality rates and health system costs
for patients with CAP or HCAP during initial hospitalization and for 1 year after hospital discharge. We
selected 50 758 patients admitted to the Veterans Affairs (VA) healthcare system between October 2003
and May 2007. Main outcome measures included hospital, post-discharge, and cumulative mortality
rates and cost during initial hospitalization and at 12 months following discharge.
Results: Hospital and 1-year HCAP mortality were nearly twice that of CAP. HCAP was an independent
predictor for hospital mortality (odds ratio (OR) 1.62, 95% conﬁdence interval (CI) 1.49–1.76) and 1-year
mortality (OR 1.99, 95% CI 1.87–2.11) when controlling for demographics, comorbidities, pneumonia
severity, and factors associated with multidrug-resistant infection, including immune suppression,
previous antibiotic treatment, and aspiration pneumonia. HCAP patients consistently had higher
mortality in each stratum of the Charlson–Deyo–Quan comorbidity index. HCAP patients incurred
signiﬁcantly greater cost during the initial hospital stay and in the following 12 months. Demographics
and comorbid conditions, particularly aspiration pneumonia, accounted for 19–33% of this difference.
Conclusion: HCAP represents a distinct category of pneumonia with particularly poor survival up to 1
year after hospital discharge. While comorbidities, pneumonia severity, and risk factors for multidrug-
resistant infection may interact to produce even higher mortality compared to CAP, they alone do not
explain the observed differences.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Pneumonia is the leading cause of infectious disease-related
death, with a ﬁnancial impact exceeding $8 billion dollars.1,2 For
nearly two decades, it has been recognized that patients previously
classiﬁed with community-acquired pneumonia (CAP) admitted
from a nursing home or those frequently exposed to the healthcare
system, suffered a disproportionately higher morbidity and
mortality.3 Accordingly, multiple schemes were developed to
better identify these patients; in 2005 the American Thoracic
Society (ATS) with the Infectious Disease Society of America (IDSA)
deﬁned a new category for lower respiratory tract infections,* Corresponding author. Tel.: +1 650 723 6381; fax: +1 650 498 6288.
E-mail address: joehsu@stanford.edu (J.L. Hsu).
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doi:10.1016/j.ijid.2011.02.002termed healthcare-associated pneumonia (HCAP).4 HCAP is
deﬁned as pneumonia in a non-hospitalized person with at least
one of the following characteristics: (1) residing in a nursing home
or long-term care facility; (2) being hospitalized within the prior
90 days; (3) receiving intravenous therapy, wound care, or
intravenous chemotherapy within the prior 30 days; or (4)
receiving hemodialysis within the previous 30 days.4
The rising incidence of bacterial resistance to previously
effective antibiotics, and the frequent emergence of novel
respiratory infections are leading to an increasing prevalence of
pneumonia.5 Because of the expanding elderly population, this
increase may disproportionately include disease likely to be
classiﬁed as HCAP. Many studies have demonstrated that HCAP
portends a signiﬁcantly poorer hospital survival than CAP (10% vs.
4%).6–9 After discharge, patients with CAP continue to suffer a
substantial health burden, with 1-year mortality rates up toses. Published by Elsevier Ltd. All rights reserved.
J.L. Hsu et al. / International Journal of Infectious Diseases 15 (2011) e382–e387 e38341%.10–12 Yet, little is known regarding post-discharge mortality
among HCAP patients, and no studies have evaluated the 1-year
differences in clinical and ﬁnancial outcomes between these two
entities. Moreover, controversy exists regarding the clinical
validity of the ATS/IDSA HCAP classiﬁcation,3 meaning that clinical
practice may vary widely, leading to over- or under-treatment,
each with potential to substantially impact patient survival.
The Department of Veterans Affairs (VA) healthcare system
comprises over 150 acute-care hospitals throughout the USA and
Puerto Rico. It has a uniform electronic health record and collects
encounter-level cost data. The VA system provides a unique
opportunity to study the epidemiology of pneumonia with
adequate numbers of patients to address the effects of multiple
covariates, including immune suppression, prior antibiotic use,
and aspiration pneumonia, which are related to infection with
multidrug-resistant (MDR) pathogens.6,13,14 Herein, we evaluated
mortality and VA healthcare cost during the index hospital stay,
and for 1 year after discharge, among patients admitted to all VA
hospitals with pneumonia during the years 2003–2007. In
addition, we evaluated the clinical validity of the ATS/IDSA HCAP
classiﬁcation. We hypothesized that the 1-year mortality rate and
VA costs would be signiﬁcantly higher for HCAP patients than for
CAP patients after controlling for demographic and clinical
variables.
2. Methods
2.1. Design, setting, and participants
We performed a retrospective analysis of hospital discharge
records from all acute-care hospitals in the VA system. This
analysis was conducted with approval from the Stanford Univer-
sity Institutional Review Board (approval number 13980).
2.2. Deﬁnitions
A pneumonia patient was deﬁned as any person admitted to an
acute care hospital with an admission and discharge diagnosis of
pneumonia (International Classiﬁcation of Diseases, Ninth Revi-
sion, Clinical Modiﬁcation (ICD-9-CM) codes 480–483, 485–487.0)
or with a discharge diagnosis of pneumonia and an admission
diagnosis of decompensated chronic obstructive pulmonary
disease (COPD) with acute exacerbation (491.21), asthma
(493.9), food/vomitus pneumonitis (507), acute respiratory failure
(518.81), acute respiratory distress (518.82), or other respiratory
distress/insufﬁciency (786.09).11 We then applied three exclusion
criteria: transfer from another hospital, less than 48 h of
antimicrobial therapy upon hospital admission, and admission
within 7 days of a prior VA hospital stay.
HCAP was deﬁned according to ATS/IDSA criteria as pneumonia
occurring outside the hospital setting in a patient who had at least
one of four criteria: (1) a VA-funded inpatient hospitalization
within 90 days prior to the index hospitalization; (2) admission
from a VA-funded long-term care stay; (3) VA-funded hemodialy-
sis within the prior 30 days; or (4) VA-funded wound care,
intravenous therapy, or chemotherapy within the prior 30 days.
VA-funded care occurs primarily at VA facilities but may be
purchased on contract from other institutions.
Following ATS major criteria, we deﬁned severe pneumonia as
occurring when a patient received either a diagnosis of shock or
invasive mechanical ventilation.15 We deﬁned an intensive care
unit (ICU) stay as one that occurred within 72 h of hospital
admission, increasing the likelihood that the ICU admission was
due to pneumonia acquired outside the hospital setting. We
stratiﬁed data by factors previously associated with an increased
risk of MDR infection, including immune suppression, aspirationpneumonia (507), and antibiotic use (any class) in the 6 months
prior to hospitalization.3,6,13,14 Immune suppression was deﬁned
as an admission or discharge diagnosis of neutropenia (288.00)
during the index hospitalization, a previous history of HIV-
infection (042), a history of any solid organ (V42) or hematopoietic
stem cell transplantation (HSCT) (41.0), or prednisone use
(>20 mg) for more than 3 weeks in the year prior to hospitaliza-
tion. While hospitalization in the previous 90 days is also
associated with MDR infection, we chose not to stratify by this
parameter, as it is an integral part of the case deﬁnition for
HCAP.4,6,14
2.3. Data sources
Clinical and demographic data came from the VA Medical SAS
Inpatient Dataset (‘PTF’) and Outpatient Dataset (‘OPC’).16 Financial
data were drawn from the VA Health Economics Resource Center
(HERC) Inpatient andOutpatientAverageCost ﬁles,which link toPTF
andOPC.17,18Byconstructionthere isaone-to-onematchof theHERC
data to inpatient stays recorded inPTF.19Outpatientpharmacy costs,
lacking in the HERC data, were extracted from the VA Decision
SupportSystem.20Deathduringthehospital staywas indicated inthe
inpatient (PTF) encounter record. One-year mortality was obtained
fromtheVABeneﬁciary IdentiﬁcationandRecordLocator Subsystem
(BIRLS).21Data fromBIRLS andPTF are combinedwithMedicare data
to create theVAVital Statusﬁle. Relative to theNationalDeath Index,
the VA Vital Status ﬁle has 98.3% sensitivity and 97.6% exact
agreement with dates.22
2.4. Statistical methods
Outcomes of interest were hospital mortality, 1-year mortality
among patients discharged from their indexed hospital admission
(termed ‘one-year post-discharge mortality’), and 1-year cumula-
tive mortality, which included mortality during or after hospitali-
zation. We extracted clinical, demographic, and cost data for each
pneumonia-related inpatient stay having admission and discharge
dates between October 2003 and the end ofMay 2007.We selected
only the ﬁrst qualifying event for each individual. To classify
comorbid illness we used the enhanced version of the Charlson–
Deyo comorbidity index developed by Quan et al., termed the
‘Charlson–Deyo–Quan (CDQ) comorbidity index’.23 Costs were
converted to 2008 dollars using the Consumer Price Index.
We calculated descriptive statistics for demographic, clinical,
and cost variables by pneumonia status. Chi-square, log-rank and
t-tests were employed as appropriate. We used Kaplan–Meier
curves and logistic regression to assess the relation of HCAP and
CAP to hospital and 12-month survival, controlling for clinical
covariates including age, CDQ comorbidity index, ICU admission,
pneumonia severity, and factors associated with MDR infections.
Analyses were carried out in SAS 9.1 (SAS Institute, Cary, NC, USA).
We estimated the marginal effect of HCAP on cost using regression
analysis with the previously described covariates. Model selection
followed standard methods.24,25 Regression analyses were per-
formed in Stata 11 (StataCorp. LP, College Station, TX, USA).
3. Results
3.1. Patient characteristics
A total of 55 963 patientsmet entry criteria. After exclusions the
ﬁnal sample numbered 50 758 stays, of which 15 578 (30.7%)
qualiﬁed as HCAP and 35 180 as CAP (69.3%) (Figure 1). Table 1
presents demographic and clinical characteristics of the study
sample. ICU admission and mechanical ventilation were more
common among HCAP patients (19.3% and 9.7%, respectively) than
[(Figure_1)TD$FIG]
55 963 Hospital stays for pneumonia 
 52 883 Admission and discharge diagnosis of pneumonia 
 3080  Admission diagnosis of another pulmonary illness,* discharge 
diagnosis of pneumonia 
5205 Stays excluded 
 3133  <48 consecutive hours of antimicrobial use upon admission 
 1102  Transfer from another hospital 
 970  VA hospitalization within 7 days prior to index admission 
50 758 Stays included 
 15 578 Met HCAP definition 
 35 180 All others classified as CAP 
Figure 1. Selection of hospital stays (*Includes decompensated chronic obstructive pulmonary disease with acute exacerbation (491.21), asthma (493.9), food/vomitus
pneumonitis (507), acute respiratory failure (518.81), acute respiratory distress (518.82), or other respiratory distress/insufﬁciency (786.09)).
Table 2











Characteristic CAP HCAP CAP HCAP CAP HCAP
All patients 5.0 9.9 17.0 34.4 21.2 40.9
Age range, years
<50 1.2 4.2 5.0 14.5 6.1 18.0
50–59 2.8 6.2 10.1 27.5 12.5 31.9
60–69 4.2 8.4 12.6 30.6 16.3 36.5
70–79 5.7 11.0 19.1 36.5 23.8 43.4
80–89 7.5 13.2 26.0 43.1 31.5 50.6
90+ 9.4 16.3 36.7 51.4 42.7 59.3
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score averaged 3 in HCAP patients and 2.5 among CAP patients.
3.2. Hospital mortality
Hospital mortality rates were nearly 2-fold higher among HCAP
patients within every stratum, with the exception of patients
admitted to the ICU and those with severe pneumonia, immune
suppression, or aspiration pneumonia (Table 2). The highest
hospital mortality was observed among HCAP patients with severe
pneumonia (38.2%). After adjustment for demographic and clinical
factors, HCAP relative to CAP was an independent predictor of
hospital mortality (odds ratio (OR) 1.62; 95% conﬁdence interval
(CI) 1.49–1.76).
3.3. One-year post-discharge mortality
A greater than 1.6-foldmortality difference 1 year after hospital
discharge was observed in all strata with the exception of patientsTable 1
Patient characteristics by HCAP statusa
CAP patients
(n = 35 180)
HCAP patients
(n=15 578)
Age (years) 69.212.9 70.312.3






Mean comorbidity scoreb 2.51.6 3.01.6
ICU admission (%) 15.2 19.3
Mechanical ventilation (%) 7.6 9.7
Severe pneumonia (%) 6.2 8.1
Aspiration pneumonia (%) 1.1 2.3
Immune suppression (%) 7.4 20.7
Prior antibiotics (%) 28.4 58.6
HCAP, healthcare-associated pneumonia; CAP, community-acquired pneumonia;
ICU, intensive care unit.
a Differences between CAP and HCAP were all statistically signiﬁcant; p<0.01.
b Based on Charlson–Deyo–Quan comorbidity index score.older than 90 years (Table 2). After controlling for demographics,
ICU admission, pneumonia severity, immune suppression, aspira-
tion pneumonia, treatment with antibiotics in the 6 months prior
to hospital admission, and CDQ comorbidity index, HCAP relativeSex
Male 5.1 10.1 17.3 34.8 21.5 41.4
Female 2.4 4.9 7.8 19.6 10.0 23.6
Comorbidity scorec
0 3.3 8.4 8.0 18.0 10.9 24.7
1 4.4 9.9 14.1 31.4 17.9 38.2
2 5.0 9.3 16.2 33.6 20.4 39.7
>3 5.8 10.3 20.8 36.9 25.4 43.4
MDR infection risk factorsd
Aspiration pneumonia 16.5 22.3 30.5 51.2 41.9 62.1
Immune suppression 9.3 13.7 26.2 42.3 32.9 50.2
Prior antibiotics 4.8 10.5 18.2 36.7 22.2 43.3
Pneumonia severitye
Less severe pneumonia 3.4 7.5 16.7 33.9 19.5 38.9
Severe pneumonia 30.3 38.2 22.9 42.2 46.2 64.1
ICU status
Non-ICU 2.9 6.6 16.4 33.2 18.8 37.6
ICU 17.2 23.9 21.0 40.6 34.6 54.8
HCAP, healthcare-associated pneumonia; CAP, community-acquired pneumonia;
ICU, intensive care unit.
a Differences between CAP and HCAP were all statistically signiﬁcant; p<0.01.
b Excludes patients who died during the index hospital admission.
c Based on Charlson–Deyo–Quan comorbidity index score.21
d MDR infection: multidrug-resistant infection risk factors.3,6,13,14
e Based on need for mechanical ventilation OR presence of shock.15
[(Figure_2)TD$FIG]
Figure 2. Kaplan–Meier survival curves by HCAP status and comorbidity score; all
HCAP–CAP comparisons were signiﬁcant (p < 0.05) by log-rank test. (Notes: CAP,
community-acquired pneumonia; HCAP, healthcare-associated pneumonia; CDQ,
Charlson–Deyo–Quan comorbidity index score.).
Table 3
VA cost by HCAP status and clinical characteristica
CAP HCAP
Initial hospital stay
LOS (days) 6.812.4 8.518.1
VA cost $11 603 $39 841 $15 243 $39 794
Marginal effectb – $2809
First year after discharge
VA cost $45 594 $151 733 $80 861 $169 321
Marginal effectb – $23 060
VA, Veterans Affairs; HCAP, healthcare-associated pneumonia; CAP, community-
acquired pneumonia; LOS, length of stay.
a Mean differences and marginal effects are all statistically signiﬁcant (p<0.01).
b Coefﬁcient on HCAP from a regression model controlling for demographic and
clinical characteristics.
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1.99, 95% CI 1.87–2.11).
3.4. One-year cumulative mortality
HCAP patients experienced higher 1-year cumulative mortality
rates than CAP patients within every stratum (Table 2). Figure 2
presents Kaplan–Meier survival curves by pneumonia category
and CDQ comorbidity score. For patients with CDQ comorbidity
scores of 2 or more, the survival gap between CAP and HCAP
patients begins immediately and widens over time. All HCAP–CAP
comparisons were signiﬁcant (p < 0.05) by log-rank test.
3.5. Factors associated with multidrug-resistant infection
Risk factors associated with MDR infections were more
prevalent in HCAP patients (Table 1). When the data were
stratiﬁed by aspiration pneumonia or immune suppression, the
mortality difference between HCAP and CAP decreased to 1.4-fold
(Table 2). Stratiﬁcation by prior antibiotic use did not change the 2-
fold mortality difference between HCAP and CAP. After hospital
discharge, having a history of aspiration pneumonia was associat-
ed with some of the highest cumulative 1-year mortality rates
(62.1%).
3.6. Health system costs
On average HCAP stays were 1.6 days (23%) longer and cost
$3640 (31%) more than CAP stays (for both differences, p < 0.01,Table 3). In regression analysis, the marginal effect of HCAP was to
add $2809 (25%) to the cost of the initial hospital stay. Among
patients alive at discharge, the estimated cost of VA healthcare in
the following year averaged $45 594 for CAP patients and $80 861
for HCAP patients. Controlling for differences in demographics and
comorbid conditions, HCAPwas associatedwith additional costs of
$23 060 (52%) over that period and reduced the HCAP–CAP
difference by 19% in the initial stay and 33% at 12 months among
survivors.
4. Discussion
In 50 758 patients treated for pneumonia in the VA, we detected
a nearly 2-fold overall mortality difference between HCAP and CAP
patients up to 1 year after discharge. This difference, which
corroborates and extends prior research showing higher hospital
mortality among HCAP than CAP patients,7,26 persisted after
consideration of age, gender, comorbidity score, pneumonia
severity, ICU status, and factors associated with MDR infections.
Our ﬁndings lend further support to classifying HCAP as a distinct
category of lower respiratory tract infection.
In previous studies, hospital mortality among CAP patients has
ranged from 4.3% to 10%.6–9,26 While our CAP ﬁndings are
consistent, the hospital mortality we observed for HCAP patients
(9.9%) is lower than results from several earlier, smaller studies
(17% to 25%).6,8,26,27 This difference may reﬂect substantial
variability in the deﬁnition of HCAP among studies.3 For example,
in the study demonstrating the highest hospital mortality, HCAP
was expansively deﬁned, including a wide variety of immune
suppressed patients.6 As 39% of HCAP patients in this study were
immune suppressed, it is not surprising that mortality was
particularly high in this cohort. In a prospective study with strictly
deﬁned ATS/IDSA HCAP criteria, the 30-day mortality of 10.3% was
similar to that observed in the current study.9
Persistence of a mortality difference between HCAP and CAP
patients after controlling for comorbidities, pneumonia severity,
and MDR infection risk factors suggests that the difference is
related to pneumonia category rather than simply a higher
prevalence of comorbidities or more severe illness in one group.
While it is not surprising that HCAP patients have a higher
mortality, as they are by deﬁnition more debilitated by comorbid-
ities, it was unexpected that the nearly 2-fold mortality difference
decreased only at extremes of illness, age (>90 years old), or
comorbidity status (CDQ 3). The persistence of a mortality
difference between HCAP and CAP suggests that the current HCAP/
CAP classiﬁcation is an important discriminator for mortality that
diminishes only when other well-described risk factors (age, CDQ
score) increase mortality for the entire cohort. Thus, while these
factors may produce even greater reductions in survival compared
to CAP, they alone do not explain the observed mortality
J.L. Hsu et al. / International Journal of Infectious Diseases 15 (2011) e382–e387e386differences. Although we are unable to completely elucidate these
differences in our administrative database, it may require
extensive chart review or prospective study to clarify the relative
contribution of these factors.
It has been suggested by previous in-hospital HCAP studies that
the difference may be related in part to initial inappropriate
antibiotics.6,7 In a retrospective analysis by Micek et al., use of
inappropriate antibiotics was more common in HCAP patients and
was an independent risk factor for mortality (adjusted OR 2.19;
95% CI 1.27–3.78).6 Similarly, we found that the mortality gap
between CAP and HCAP decreased after controlling for severe
pneumonia, immune suppression, and aspiration pneumonia,
three factors that have been associated with increased risk for
infection with MDR pathogens. Because patients with MDR
infections have a higher risk of initial inappropriate antibiotic
therapy, this may explain in part some of the mortality differences
between pneumonia categories. Unfortunately we were unable to
directly evaluate this hypothesis with our data. Alternatively,
mortalitymay differ by differential pneumonia severity, criteria for
ICU admission, or prevalence of culture positivity, as observed in
smaller prospective analyses.27,28
Greater costs for HCAP patients were due in part to
demographic and clinical differences. Controlling for covariates
reduced the HCAP–CAP cost difference by 19% in-hospital and by
33% at 1 year. We believe that residual differences are due to the
higher mortality rate among HCAP patients coupled with greater
intensity and cost of healthcare services around the time of
death.
To our knowledge, this is the ﬁrst study to characterize the 1-
year clinical and ﬁnancial impact of HCAP. The study’s strength
lies in our strictly deﬁned HCAP deﬁnition and in the large
sample size, which allowed us to adjust for multiple covariates
in our analysis. However, several study limitations deserve
mention. Two are speciﬁc to the VA: nearly all patients were
male, and analyses could not be stratiﬁed by race due to
incomplete data. Thus, the external generalizability of our
results is uncertain. In addition, the use of ICD-9-CM codes to
deﬁne disease may have led to misclassiﬁcation bias, although
our inclusion and exclusion criteria and large sample size may
have lessened the impact of misclassiﬁcation. Multiple studies
have shown that ICD-9 codes for pneumonia compared with
chart review demonstrate moderately high sensitivity for
detecting CAP.29–31 Toward this end, the proportion of HCAP
patients (30.7%) reported in this study is similar to that reported
in a prospective, multicenter, point prevalence study (28%).26
Although we were unable to classify patients in this adminis-
trative database by their functional status, an independent risk
factor for MDR pathogens, we did stratify our data by the
incidence of aspiration pneumonia.3 Studies have shown that
dependency for feeding (a marker of poor functional status) also
is a risk factor for aspiration pneumonia.3,32 Thus, at least one
aspect of functional status could be investigated and did
correlate with our primary ﬁndings. Another potential limitation
was our inability to identify patients with ‘do not resuscitate’
orders, which would limit aggressiveness of treatment and may
differentially impact survival. In contrast to previous HCAP
studies, rates of ICU admission and mechanical ventilation were
higher in HCAP than CAP patients, suggesting that a treatment
ceiling effect potentially more prevalent in HCAP patients did
not substantially bias our results.9,28
In conclusion, this study supports HCAP as a distinct category
by showing it is associated with particularly poor survival up to 1
year after hospital discharge and that HCAP patients create
substantially greater costs for the healthcare system. Themortality
difference between CAP and HCAP persisted after controlling for
multiple demographic and clinical factors, including factorsassociated with MDR infections. HCAP patients admitted to the
ICU with severe pneumonia represented a sub-group with
particularly high mortality. Knowledge of this disparity may help
improve post-discharge surveillance and palliative care in patients
with low probability for survival. Further study is needed to
evaluate whether inappropriate antibiotic use among patients
with HCAP contributes to the observed mortality difference
between CAP and HCAP.
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